Notice: This company has been marked as potentially delisted and may not be actively trading. Amedica (AMDA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends AMDA vs. TLSI, SGHT, PDEX, SRTS, TELA, LNSR, MGRM, GUTS, NSPR, and WOKShould you be buying Amedica stock or one of its competitors? The main competitors of Amedica include TriSalus Life Sciences (TLSI), Sight Sciences (SGHT), Pro-Dex (PDEX), Sensus Healthcare (SRTS), TELA Bio (TELA), LENSAR (LNSR), Monogram Orthopaedics (MGRM), Fractyl Health (GUTS), InspireMD (NSPR), and WORK Medical Technology Group LTD Ordinary Shares (WOK). These companies are all part of the "medical" sector. Amedica vs. TriSalus Life Sciences Sight Sciences Pro-Dex Sensus Healthcare TELA Bio LENSAR Monogram Orthopaedics Fractyl Health InspireMD WORK Medical Technology Group LTD Ordinary Shares TriSalus Life Sciences (NASDAQ:TLSI) and Amedica (NASDAQ:AMDA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation, community ranking and media sentiment. Do insiders & institutionals believe in TLSI or AMDA? 2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 3.7% of Amedica shares are held by institutional investors. 32.8% of TriSalus Life Sciences shares are held by company insiders. Comparatively, 0.9% of Amedica shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts prefer TLSI or AMDA? TriSalus Life Sciences presently has a consensus target price of $11.79, suggesting a potential upside of 130.64%. Given TriSalus Life Sciences' stronger consensus rating and higher probable upside, research analysts clearly believe TriSalus Life Sciences is more favorable than Amedica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TriSalus Life Sciences 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22Amedica 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community prefer TLSI or AMDA? Amedica received 295 more outperform votes than TriSalus Life Sciences when rated by MarketBeat users. However, 100.00% of users gave TriSalus Life Sciences an outperform vote while only 64.90% of users gave Amedica an outperform vote. CompanyUnderperformOutperformTriSalus Life SciencesOutperform Votes12100.00% Underperform VotesNo VotesAmedicaOutperform Votes30764.90% Underperform Votes16635.10% Which has more risk & volatility, TLSI or AMDA? TriSalus Life Sciences has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Amedica has a beta of -1.24, indicating that its stock price is 224% less volatile than the S&P 500. Which has higher earnings & valuation, TLSI or AMDA? Amedica has lower revenue, but higher earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Amedica, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTriSalus Life Sciences$18.51M8.42-$59.04M-$2.49-2.05Amedica$11.23M3.22-$9.32M-$3.13-0.97 Does the media prefer TLSI or AMDA? In the previous week, TriSalus Life Sciences had 12 more articles in the media than Amedica. MarketBeat recorded 12 mentions for TriSalus Life Sciences and 0 mentions for Amedica. TriSalus Life Sciences' average media sentiment score of 1.02 beat Amedica's score of 0.00 indicating that TriSalus Life Sciences is being referred to more favorably in the media. Company Overall Sentiment TriSalus Life Sciences Positive Amedica Neutral Is TLSI or AMDA more profitable? Amedica has a net margin of -139.62% compared to TriSalus Life Sciences' net margin of -206.24%. TriSalus Life Sciences' return on equity of 0.00% beat Amedica's return on equity.Company Net Margins Return on Equity Return on Assets TriSalus Life Sciences-206.24% N/A -236.83% Amedica -139.62%-148.60%-67.83% SummaryTriSalus Life Sciences beats Amedica on 13 of the 19 factors compared between the two stocks. Get Amedica News Delivered to You Automatically Sign up to receive the latest news and ratings for AMDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMDA vs. The Competition Export to ExcelMetricAmedicaSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.20M$4.91B$5.62B$9.14BDividend YieldN/A52.56%5.36%3.98%P/E Ratio-0.9726.4289.6917.66Price / Sales3.2253.761,219.4081.09Price / CashN/A52.0644.3437.71Price / Book1.698.245.134.73Net Income-$9.32M$13.79M$118.85M$225.42M Amedica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMDAAmedicaN/A$3.05-1.9%N/A+937.4%$36.20M$11.23M-0.97N/ATLSITriSalus Life Sciences3.8283 of 5 stars$4.86-1.4%$11.79+142.5%-45.3%$148.18M$18.51M-1.95106Insider TradeNews CoveragePositive NewsGap UpSGHTSight Sciences3.8061 of 5 stars$2.89+2.1%$4.72+63.3%-35.2%$146.70M$81.06M-2.83210Analyst ForecastPDEXPro-Dex3.5242 of 5 stars$44.32-0.1%$52.00+17.3%+92.3%$144.48M$53.84M28.78140Earnings ReportInsider TradeSRTSSensus Healthcare3.5153 of 5 stars$6.84+4.3%$12.50+82.7%+93.6%$107.51M$41.31M12.0040Upcoming EarningsShort Interest ↑News CoverageTELATELA Bio2.7323 of 5 stars$2.63-2.2%$9.25+251.7%-60.4%$103.60M$58.45M-1.56120LNSRLENSAR1.1417 of 5 stars$8.17-1.8%$8.00-2.1%+231.0%$94.85M$42.16M-5.60110Positive NewsMGRMMonogram Orthopaedics3.3042 of 5 stars$2.68+4.3%$4.00+49.3%-18.4%$91.95M$370,000.00-5.7028Short Interest ↓News CoveragePositive NewsGUTSFractyl Health1.6135 of 5 stars$1.82+0.8%$22.00+1,112.1%N/A$87.30M$97,000.00-0.15102Short Interest ↑NSPRInspireMD2.5755 of 5 stars$2.94+8.1%$4.75+61.6%-20.1%$76.68M$6.20M-3.9250Analyst ForecastNews CoverageGap UpWOKWORK Medical Technology Group LTD Ordinary SharesN/A$4.95-1.2%N/AN/A$71.78MN/A0.00226 Related Companies and Tools Related Companies TriSalus Life Sciences Competitors Sight Sciences Competitors Pro-Dex Competitors Sensus Healthcare Competitors TELA Bio Competitors LENSAR Competitors Monogram Orthopaedics Competitors Fractyl Health Competitors InspireMD Competitors WORK Medical Technology Group LTD Ordinary Shares Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AMDA) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredTrump’s back in the oval office. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. And he says 2025 could be...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amedica Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
